Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reiterated by investment analysts at Peel Hunt in a research report issued on Monday, ThisIsMoney.Co.Uk reports.
Other equities research analysts have also recently issued reports about the company. FinnCap started coverage on Circassia Pharmaceuticals in a report on Thursday, September 26th. They issued a “corporate” rating and a GBX 80 ($1.05) target price on the stock. Peel Hunt reaffirmed a “buy” rating and issued a GBX 70 ($0.91) target price on shares of Circassia Pharmaceuticals in a report on Tuesday, October 15th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. Circassia Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of GBX 79 ($1.03).
Shares of CIR stock opened at GBX 16.75 ($0.22) on Monday. Circassia Pharmaceuticals has a 12-month low of GBX 13.25 ($0.17) and a 12-month high of GBX 72.20 ($0.94). The company has a current ratio of 0.40, a quick ratio of 0.35 and a debt-to-equity ratio of 21.61. The stock’s 50-day moving average price is GBX 17.10 and its 200-day moving average price is GBX 21.35. The stock has a market capitalization of $62.84 million and a price-to-earnings ratio of -0.50.
In related news, insider Jonathan Emms purchased 300,000 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was bought at an average price of GBX 17 ($0.22) per share, for a total transaction of £51,000 ($66,640.53).
Circassia Pharmaceuticals Company Profile
Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD).
See Also: What factors cause inflation to rise?
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.